Ashwani Bahl, Andrew J Leishman, Matthew Carr, Stuart Thomson, Adrian Campbell, Edward Ainscow
CT7439 an oral first-in class selective CDK12/13 Inhibitor and Cyclin K degrader: Mechanistic profiling and combination efficacy in an ovarian cancer model
May. 27, 2025
Patient selection biomarkers for CDK7 inhibitor samuraciclib (SAM; CT7001) combined with selective estrogen receptor degrader (SERD) in hormone receptor-positive advanced breast cancer (HR+ ABC) post-CDK4/6 inhibitor (CDK4/6i)
May. 15, 2025
Mafalda Oliveira, Begoña Bermejo, Einav Gal-Yam, María Gion, Sara A Hurvitz, Seock-Ah Im, Kyung Hae Jung, Cristina Saavedra, Saeed Sadeghi, Amir Sonnenblick, Seth A Wander, Stuart McIntosh, Charles Coombes, Hope S. Rugo
Cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib combined with selective estrogen receptor degrader (SERD) elacestrant in advanced HR+ breast cancer after CDK4/6i: dose escalation data from the Phase 1b/2 SUMIT-ELA study
Dec. 11, 2024
Francois-Clement Bidard, Maxime Brunet, Amita Patnaik, Cécile Vicier, Raquel Gomez, Sacha Howell, Luisa Sanchez, Erin Roesch, Mario Campone, Agostina Stradella, Simon Lord, Carlos Garay, Paolo Mazzei, Glen Clack, Stuart McIntosh, William Gradishar
Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: phase 2 SUMIT-BC study
Jun. 02, 2024
Sonia Pernas, Carmen Hinojo, Javier Pascual, Sercan Aksoy, Glen Clack, Stuart McIntosh
SUMIT-BC: Phase 2 randomized study of fulvestrant with or without the cyclin-dependent kinase 7 inhibitor samuraciclib in advanced hormone receptor-positive breast cancer after CDK4/6 inhibitor
Dec. 05, 2023
Glen Clack, Sercan Aksoy, Meritxell Bellet-Ezquerra, Begoña Bermejo de las Heras, Arslan Cagatay, Maria Castro-Henriques Pinto-Machado, Irfan Cicin, Mahmut Gumus, Carmen Hinojo-González, Nuri Karadurmus, Denisse Lee Cervantes, Rebeca Lozano Mejorada, Emmanuel de la Mora Jimenez, Fernando Moreno Anton, Sonia Pernas, Timothy J. Pluard, Carlos Zuloaga Fernandez del Valle, Ozan Yazıcı, Stuart McIntosh
SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor samuraciclib and selective estrogen receptor degrader elacestrant in advanced hormone receptor positive breast cancer after CDK4/6 inhibitor
Dec. 05, 2023
Amita Patnaik, Silvia Antolín Novoa, Meritxell Bellet-Ezquerra, François-Clément Bidard, Valentina Boni, Maxime Brunet, Mario Campone, Carlos Garay, Raquel Gómez-Bravo, Sacha J. Howell, Rinath M. Jeselsohn, Simon Lord, Paolo Mazzei, Maria de Miguel Luken, Erin Roesch, Agostina Stradella, Helene Vanacker, Cecile Vicier, Seth A. Wander, Glen Clack, Stuart McIntosh
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Jul. 24, 2023
R. Charles Coombes , Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh & Matthew G. Krebs
Identification of an orally bioavailable dual Cyclin-K glue degrader – CDK12/13 inhibitor’
Dec. 01, 2021
Edward K. Ainscow, Adrian Campbell, Michael Cripps, Robert Workman, Stuart Thomson, Kam Chohan, Samien Crepin, Mahiro Sunose, Jamie Patient, Jane Kendrew, Ash Bahl
Identification of novel CDK12 inhibitors that synergize with PARP inhibition through induction of ‘BRCAness’ phenotype
Jun. 01, 2020
Edward K. Ainscow
Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer
Dec. 09, 2021
M.G. Krebs, S. Lord, L. Kenny, R.D. Baird, I. MacPherson, A. Bahl, G. Clack, E. Ainscow, A.G. Barrett, P. Dickinson, M.J. Fuchter, M. Lehnert, S. Ali, S. Mcintosh, R.S. Coombes